The Prostate and Urologic Cancer Research Group conducts and supports research on the prevention and early detection of prostate and bladder cancer. Clinical trials and the evaluation of new agents, surrogate biomarkers, and new technologies to identify premalignant lesions are developed and supported.
Funding Opportunity Announcements (FOA)
Funding Opportunity Title: Biology of Bladder Cancer (R01 Clinical Trial Optional)
Activity Code: R01 Research Project Grant
Announcement Type: New
Companion Funding Opportunity: PAR-19-184, R21 Exploratory/Developmental Grant
Funding Opportunity Purpose
This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Cancer Prevention Clinical Trials Network (CP-CTNet)
Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.
Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
Major medical research centers conduct systematic early clinical development of promising preventive agents.
Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard Parnes
In 2003, results from the Prostate Cancer Prevention Trial (PCPT)—an NCI-funded randomized clinical trial with nearly 19,000 participants—showed that men aged 55 and older who used the drug finasteride daily for 7 years had a substantially reduced risk of developing prostate cancerExit Disclaimer.
DCP Blog Post: Preventing the Progression of Low-Risk Localized Prostate Cancers: A New Frontier
In the path toward understanding the development and ultimate prevention of prostate cancer, researchers are studying how to keep low-grade, early stage prostate cancer being monitored on Active Surveillance from progressing to disease that needs definitive treatment.